News
BMRN
89.78
-0.33%
-0.30
Notable Friday Option Activity: TWLO, VRT, BMRN
NASDAQ · 5h ago
Novartis (NVS) to Report Q1 Earnings: What to Expect?
NASDAQ · 10h ago
Guru Fundamental Report for BMRN - Benjamin Graham
NASDAQ · 1d ago
Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market Expectations
TipRanks · 4d ago
Weekly Report: what happened at BMRN last week (0408-0412)?
Weekly Report · 4d ago
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN)
TipRanks · 04/12 12:33
Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Nurix Therapeutics (NRIX)
2 analysts have maintained Buy ratings on BioMarin Pharmaceutical and Nurix Therapeutics. Barclays analyst Gena Wang maintained a Buy rating on the Healthcare sector stock today. The company’s shares closed last week at $90.21. The analyst consensus on Nurix is a Strong Buy.
TipRanks · 04/11 07:11
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 04/09 02:40
Weekly Report: what happened at BMRN last week (0401-0405)?
Weekly Report · 04/08 09:13
Looking Into Biomarin Pharmaceutical's Recent Short Interest
Biomarin Pharmaceutical's short percent of float has fallen 3.07% since its last report. The company has 2.96 million shares sold short, which is 1.58% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 04/03 18:00
Weekly Report: what happened at BMRN last week (0325-0329)?
Weekly Report · 04/01 09:12
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has US$16.5b in debt, but has a healthy balance sheet. The company has barely any net debt, and its debt is offset by its free cash flow. It grew its EBIT by 150% over the last 12 months. The balance sheet is a good indicator of a company's ability to manage its debt. But the real risk resides within the company's use of debt.
Simply Wall St · 03/30 13:31
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/28 13:40
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)
TipRanks · 03/26 11:10
BioMarin Pharmaceutical's Voxzogo Opportunities Being Underappreciated -- Market Talk
UBS believes expansion opportunities for BioMarin's Voxzogo could bring in $3 billion to $4 billion in revenue. The drug is currently used to treat achondroplasia, a genetic condition. The analysts say data indicates the drug could be expanded to treat other conditions. Shares of the company tick up 1.5%.
Dow Jones · 03/25 19:34
Weekly Report: what happened at BMRN last week (0318-0322)?
Weekly Report · 03/25 09:12
Biomarin Pharmaceutical Inc: Statement of changes in beneficial ownership of securities
Press release · 03/20 01:39
Weekly Report: what happened at BMRN last week (0311-0315)?
Weekly Report · 03/18 09:12
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Four growth stocks you'll regret not buying in the new Nasdaq bull market. The Nasdaq Composite has hit an all-time high. PayPal Holdings and Fiverr International are among the growth stocks investors should consider buying. The two companies are in the midst of their respective bull and bear markets. The growth stock-driven Nasdaq is a great place to start.
The Motley Fool · 03/16 09:06
Buy Rating Justified by Voxzogo’s Efficacy in Hypochondroplasia Treatment: A Deep Dive into BioMarin Pharmaceutical’s Clinical Data
TipRanks · 03/13 12:25
More
Webull provides a variety of real-time BMRN stock news. You can receive the latest news about Biomarin Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRN
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.